<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7239338\results\search\country\results.xml">
  <result pre="highly pathogenic species have been identified in humans: Zaire ebolavirus," exact="Sudan" post="ebolavirus, Taï Forest ebolavirus, and Bundibugyo ebolavirus.14Zaire ebolavirus is"/>
  <result pre="2013–2016 West Africa outbreak and the current Democratic Republic of" exact="Congo" post="outbreak, responsible of &amp;gt; 95% of the reported fatality"/>
  <result pre="since its discovery in 1976. Spread over Guinea, Liberia, and" exact="Sierra Leone," post="28,616 cases of patients with EVD have been reported,"/>
  <result pre="candidates was favipiravir (T�?705), an RNA polymerase inhibitor approved in" exact="Japan" post="for the treatment of noncomplicated influenza infections and in"/>
  <result pre="of noncomplicated influenza infections and in clinical development in the" exact="United States." post="Favipiravir is an oral drug with a fast absorption"/>
  <result pre="an open multicenter nonrandomized clinical trial that took place in" exact="Guinea" post="from December 2014 to April 2015.37 JIKI was the"/>
  <result pre="brincidofovir, and convalescent plasma were implemented in Gunea, Liberia, and" exact="Sierra Leone" post="during the 2013–2016 outbreak, yet none of them could"/>
  <result pre="with 10 to 1,000 focus forming units with Ebola virus" exact="Gabon" post="2001 strain, belonging to Zaire ebolavirus species. Viral load"/>
  <result pre="Accordingly, a first experiment was designed where cynomolgus macaques from" exact="Mauritius" post="Island were infected 2 days after the initiation of"/>
  <result pre="drug half�?maximal effective concentration for various emerging viruses. CCHFV, Crimea" exact="Congo" post="haemorrhagic fever virus; EBOV, Ebola virus; JUNV, Junin virus;"/>
  <result pre="150 or 180 mg/kg were conducted in cynomolgus macaques from" exact="Mauritius" post="Island using the same design (i.e., with treatment starting"/>
  <result pre="exposed people. The promising vesicular stomatitis virus�?based vaccine used in" exact="Guinea" post="provided high level protection after a 10�?day delay, but"/>
  <result pre="prophylaxis or postexposure setting. During the last Marburg outbreak in" exact="Uganda" post="in October 2017, favipiravir was considered for such a"/>
  <result pre="Research Program on Emerging and Re�?emerging Infectious Diseases of the" exact="Japan" post="Agency for Medical Research and Development (AMED). Conflict of"/>
  <result pre="of Interest As Editor�?in�?Chief for CPT: Pharmacometrics &amp;amp; Systems Pharmacology," exact="France" post="Mentré was not involved in the review or decision"/>
  <result pre="J.S.et alClinical illness and outcomes in patients with Ebola in" exact="Sierra Leone." post="N. Engl. J. Med.371, 2092–2100 (2014).25353969 18Olejnik, J., Ryabchikova,"/>
  <result pre="virus RNA in semen for six months after returning from" exact="Haiti" post="to Italy, January 2016. Eurosurveillance21, (2016). 84Osuna, C.E. &amp;amp;"/>
  <result pre="rVSV�?vectored vaccine expressing Ebola surface glycoprotein: interim results from the" exact="Guinea" post="ring vaccination cluster�?randomised trial. Lancet386, 857–866 (2015).26248676 91Marzi, A.et"/>
 </snippets>
</snippetsTree>
